Amid rapid advances in DNA sequencing, MGI Tech Co., Ltd. (MGI) continues to make genomics more accessible. Since the Human Genome Project, whole-genome sequencing costs have fallen from nearly $3 billion over 13 years to less than $1,000 today. The quest for faster, higher-throughput, and lower-cost sequencing continues.
MGI’s latest ultra-high-throughput sequencer, DNBSEQ-T7*, powered by DNBSEQ™ technology*, delivers a technological breakthrough in performance and cost. It integrates advances in biochemistry, fluidics, and optics to enhance efficiency and productivity.
High speed, flexibility, and ultra-high throughput
DNBSEQ-T7* uses DNA nanoball and combinatorial probe anchor synthesis technologies to produce up to 60 human genomes per day. Its 20% higher chip density enables single-chip Tb-level output, reaching up to 6Tb per day. Quadruple flowcell staging allows one to four independent flowcells to run simultaneously, saving time and cost. Proprietary technology ensures high accuracy, low duplicates, and minimal index hopping. The V2.0 sequencing reagent set* improves data output, reduces mismatches and duplicate rates, and enhances precision and sensitivity.
Applications from pandemic response to precision medicine
DNBSEQ-T7* supports whole-genome sequencing, ultra-high-depth exome sequencing, epigenome sequencing, tumor gene detection, and more. During the COVID-19 pandemic, it enabled rapid sequencing of SARS-CoV-2, informing diagnostics and vaccine development. Globally, businesses like Gencell Pharma (Colombia) and GrandOmics (China) use T7* for precision medicine research. It also supports gene editing studies, such as CRISPR-Cas12f1 off-target analysis, producing high-quality whole-genome sequencing data for verification.
Comprehensive, one-stop service
T7* provides end-to-end sequencing support, from sample pretreatment, library preparation, and online sequencing to data analysis. Features include automated cleaning and slide recovery, continuous running, and optional automation equipment for pre- and post-sequencing processes. This high degree of automation maximizes throughput and reduces labour and material costs. Commercialization of DNBSEQ-T7* is expected to lower whole-genome sequencing costs to under $500, solidifying MGI’s position as a leader in the gene-sequencing industry.
*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, and Austria.
